EXHIBIT 99







                     CEL-SCI SECURES MANUFACTURING FACILITY
                            FOR MULTIKINE CANCER DRUG

Biomedical Real Estate Group Backs Construction of Facility

VIENNA, VA, AUGUST 14, 2007 -- CEL-SCI CORPORATION (AMEX: CVM) announced today
that it has entered into an agreement with a biomedical real estate group under
which CEL-SCI acquires long term use of a dedicated manufacturing facility for
its cancer drug Multikine(R). The financial value of this transaction to CEL-SCI
is about $15 million. This facility is located near Baltimore, Maryland. Once
fully built out to CEL-SCI's specifications, the facility will produce Multikine
for both its Phase III clinical trials for head and neck cancer, as well as
other cancers, and following marketing approval, for sale. This transaction is
of great importance to CEL-SCI because it allows the Company to preserve its
cash and, at the same time, pursue the development of its cancer drug in the
most prudent manner.

BioRealty, Inc., a privately held real estate firm specializing in the
biomedical sector, acquired the facility and is responsible for its build out
pursuant to CEL-SCI's specifications. CEL-SCI leases the facility for 20 years,
with options to extend the lease or purchase the facility at a later time.
BioRealty, Inc. also committed to provide development management services and
funding for the build-out of this facility, which, once fully built out, will be
able to supply over $1 billion worth of drug. The Company had entered into a
letter of intent with BioRealty on this transaction in January 2007.

The manufacturing facility will allow the Company to produce Multikine, a
biologic, in the same manufacturing facility for Phase III clinical trials as
for commercial production. Regulatory authorities prefer to see biologics such
as Multikine produced in the same manufacturing facility for Phase III clinical
trials and the sale of the product because this arrangement helps to ensure that
the drug lots used to conduct the clinical trials will be consistent with those
that will be marketed subsequent to approval.

Although some biotech companies outsource their manufacturing, this can be risky
with biologics because they require intense manufacturing and process control.
With biologic products a minor change in manufacturing and process control can
result in a major change in the final product. Good and consistent manufacturing
and process control is critical and is best assured if the product is
manufactured and controlled in the manufacturer's own facility by their own
specially trained personnel. In fact, there have been many situations in which
companies had to repeat their Phase III trials or perform an additional clinical
bridging study to address regulatory concerns resulting from outsourced
manufacturing. This has led to enormous costs and lengthy delays in getting
biotech drugs to market. In addition, using a contract manufacturer ties the
company's approval to the manufacturing facility of the contractor, further
reducing the level of control by the company.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "Manufacturing biologics
is such an expensive endeavor that most biotech companies partner with larger
companies, and in the process give up their marketing rights. The funding with
BioRealty, Inc. will allow us to keep the marketing rights, thereby giving our
shareholders the greatest value creation. Now that the significant hurdle of
manufacturing has been tackled, we are able to focus on getting Multikine
through Phase III, and ultimately to patients."

Stan Wendzel, Managing Director of BioRealty, Inc. said, "After having completed
the due diligence on both CEL-SCI and its Multikine product, we recognized that
CEL-SCI may fundamentally change the standard method for treating cancer in the
future. At the same time we also recognize the challenges faced by any Phase III
biotech company wishing to self-fund a manufacturing facility. With CEL-SCI's
help we were able to devise a client-tailored financing approach for their
facility, which allows CEL-SCI to preserve its capital and focus on its core
business. CEL-SCI has a dedicated and highly capable management team that we
believe will succeed in bringing to market a major new cancer drug. We are
simply pleased to be helping CEL-SCI accomplish that goal."

In Phase II clinical trials Multikine was shown to be safe and well-tolerated,
and to improve the patients' overall survival by 33% at a median of three and a
half years following surgery. The U.S. Food and Drug Administration (FDA) gave
the go-ahead for a Phase III clinical trial with Multikine in January 2007 and
granted Orphan drug status to Multikine in the neoadjuvant therapy of squamous
cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the
first immunotherapeutic agent in a new class of drugs called "Immune
SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts
in defending us against cancer. As opposed to other immunotherapies, which are
designed to target a single or limited number of specific antigens or molecules,
Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and
targeted killing of the specific tumor cells and they activate the immune system
to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a
first-line standard of care treatment for cancer. It is administered prior to
any other cancer therapy because that is the period when the anti-tumor immune
response can still be fully activated. Once the patient has advanced disease, or
had surgery or has received radiation and/or chemotherapy, the immune system is
severely weakened and is less able to mount an effective anti-tumor immune
response. Other immunotherapies are administered later in cancer therapy, which
can limit their effectiveness.

CEL-SCI Corporation is developing new immune system based treatments for cancer
and infectious diseases. The Company has operations in Vienna, Virginia and
Baltimore, Maryland. The Company's lead product Multikine is cleared to enter a
global Phase III clinical trial in advanced primary head and neck cancer
patients in the U.S. and Canada. CEL-SCI's other products, which are currently
in pre-clinical stage, have shown protection against a number of diseases in
animal tests and are being tested against diseases associated with bio-defense
and avian flu.

When used in this report, the words "intends," "believes," "anticipated" and
"expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which could
cause actual results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective, receiving
necessary regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary capital and the
risk factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10-K for the year ended
September 30, 2006. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking statements which may be made to
reflect the events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.

# # #

If you would like to be removed from future e-mail notifications, please reply
to cel-sci@cel-sci.com and type REMOVE in the subject line. We apologize for any
inconvenience.